Heximar-B Ointment is a topical formulation containing Betamethasone 0.05% w/w, a potent corticosteroid, and Calcipotriol 0.005% w/w, a synthetic vitamin D3 analogue. This combination is indicated for the treatment of chronic plaque psoriasis, providing both anti-inflammatory and antiproliferative effects. Betamethasone exerts its therapeutic action by suppressing inflammatory responses, reducing erythema, pruritus, and scaling associated with psoriatic lesions. Calcipotriol modulates keratinocyte differentiation and proliferation, thereby normalizing epidermal growth and reducing plaque formation. The ointment base facilitates effective skin penetration and sustained drug delivery. Heximar-B Ointment is typically applied once or twice daily to affected areas, with treatment duration guided by clinical response and physician assessment. Caution is advised in patients with known hypersensitivity to corticosteroids or vitamin D analogues. Prolonged use should be avoided to minimize the risk of local adverse effects such as skin atrophy, telangiectasia, and potential systemic corticosteroid absorption. It is contraindicated in patients with disorders of calcium metabolism or hypercalcemia. Regular monitoring is recommended during extended therapy. Heximar-B Ointment offers a synergistic approach to psoriasis management, combining anti-inflammatory and keratinocyte-modulating actions to improve clinical outcomes.